Discovery of new Biomarkers

Acobiom (Montpellier, France) is focused on the identification of RNA/DNA Biomarkers to improve diagnostics and treatments. These RNA/DNA Biomarkers could be applied in several activities including: treatment response prediction, treatment efficiency, disease detection and classification, patient stratification, etc.

Our approach to discover new Biomarkers

Acobiom’s approach to discover new RNA/DNA Biomarkers is based on Next-Generation Sequencing (NGS), the investigation of gene expression changes, the analyses of biological phenoty

During the course of its R&D and its service activitiy, Acobiom identified dozens of RNA/DNA Biomarkers in correlation with therapies/drugs, cognitive score/impairment, disease detection, evolution and prognosis, immune response, vaccination, infectious diseases, and pharmacogenomics.
These Biomarkers were identified in different types of tissues, organs, and for specific biological questions.

Moreover, some of its researches, collaborations or partnerships have issued scientific publications.

To obtain more information concerning the expertise of Acobiom in the identiication of RNA/DNA Biomarkers, and in its technology know-how in genomics, pharmacogenomics, transcriptomics, bioinformatics, please download the document: « ACOBIOM Expertises »

If you need more information, please contact our Business Development department
(T: +33(0)467 419 748, Email: busdev@acobiom.com).